{"transactions":[{"id":4634641,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:19:54.000Z","date":"2026-09-30","kind":"grant","planned":false,"acquired":true,"shares":9727,"price":2.18,"value":21204.86,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Issuer's 2020 Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of April 1, 2026 through September 30, 2026. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on April 1, 2026."}],"balance_after":43059,"source":{"system":"sec-edgar","filing":"0001628280-26-064317","document":"wk-form4_1790889591.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000162828026064317/wk-form4_1790889591.xml","form_type":"4"}},{"id":681817,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":21771,"kind":"organization","name":"WALTERS GROUP","position":1,"cik":"0001177523","reported_name":"WALTERS GROUP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21772,"kind":"person","name":"WALTERS WILLIAM THURMAN","position":2,"cik":"0001689655","reported_name":"WALTERS WILLIAM THURMAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21773,"kind":"person","name":"WALTERS SUSAN BERKLEY","position":3,"cik":"0001689761","reported_name":"WALTERS SUSAN BERKLEY","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-08-19T22:11:25.000Z","date":"2026-08-14","kind":"purchase","planned":false,"acquired":true,"shares":4335000,"price":3.5,"value":15172500.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock reported herein (the \"Shares\") are held directly by The Walters Group (the \"TWG\"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares of common stock reported herein (the \"Shares\") are held directly by The Walters Group (the \"TWG\"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares of common stock reported herein (the \"Shares\") are held directly by The Walters Group (the \"TWG\"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose."}],"balance_after":17844973,"source":{"system":"sec-edgar","filing":"0001213900-26-091823","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177523/000121390026091823/ownership.xml","form_type":"4"}},{"id":732922,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:09:11.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":307521,"source":{"system":"sec-edgar","filing":"0001808098-26-000003","document":"wk-form4_1781813348.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000180809826000003/wk-form4_1781813348.xml","form_type":"4"}},{"id":732121,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:08:42.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":264254,"source":{"system":"sec-edgar","filing":"0001838042-26-000003","document":"wk-form4_1781813319.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804226000003/wk-form4_1781813319.xml","form_type":"4"}},{"id":732119,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":35157,"kind":"person","name":"Walker Luke Nathaniel","position":1,"cik":"0001701440","reported_name":"Walker Luke Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:07:57.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":201384,"source":{"system":"sec-edgar","filing":"0001701440-26-000004","document":"wk-form4_1781813274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000170144026000004/wk-form4_1781813274.xml","form_type":"4"}},{"id":732120,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36822,"kind":"person","name":"Kariuki Enoch","position":1,"cik":"0001843119","reported_name":"Kariuki Enoch","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:07:01.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":194465,"source":{"system":"sec-edgar","filing":"0001843119-26-000003","document":"wk-form4_1781813217.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000184311926000003/wk-form4_1781813217.xml","form_type":"4"}},{"id":732117,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-18T20:06:11.000Z","date":"2026-06-16","kind":"grant","planned":false,"acquired":true,"shares":57100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2027 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":395895,"source":{"system":"sec-edgar","filing":"0001356256-26-000005","document":"wk-form4_1781813168.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000135625626000005/wk-form4_1781813168.xml","form_type":"4"}},{"id":761871,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":34817,"kind":"person","name":"Campbell Shannon","position":1,"cik":"0002018966","reported_name":"Campbell Shannon","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-27T20:11:29.000Z","date":"2026-05-26","kind":"grant","planned":false,"acquired":true,"shares":114200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The restricted stock units (\"RSUs\") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":114200,"source":{"system":"sec-edgar","filing":"0002018966-26-000005","document":"wk-form4_1779912686.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201896626000005/wk-form4_1779912686.xml","form_type":"4"}},{"id":912081,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:49.000Z","date":"2026-02-09","kind":"sale","planned":false,"acquired":false,"shares":335,"price":2.3929,"value":801.6215,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":33332,"source":{"system":"sec-edgar","filing":"0001838041-26-000004","document":"wk-form4_1770775846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804126000004/wk-form4_1770775846.xml","form_type":"4"}},{"id":912080,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:49.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":2962,"price":2.4297,"value":7196.7714,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":33667,"source":{"system":"sec-edgar","filing":"0001838041-26-000004","document":"wk-form4_1770775846.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804126000004/wk-form4_1770775846.xml","form_type":"4"}},{"id":912078,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and PFO"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:25.000Z","date":"2026-02-10","kind":"sale","planned":true,"acquired":false,"shares":6894,"price":2.4223,"value":16699.3362,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 18, 2025."}],"balance_after":146506,"source":{"system":"sec-edgar","filing":"0002018766-26-000006","document":"wk-form4_1770775823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201876626000006/wk-form4_1770775823.xml","form_type":"4"}},{"id":912077,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and PFO"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:25.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":3379,"price":2.3929,"value":8085.6091,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":153400,"source":{"system":"sec-edgar","filing":"0002018766-26-000006","document":"wk-form4_1770775823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201876626000006/wk-form4_1770775823.xml","form_type":"4"}},{"id":912076,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and PFO"}}],"security":"Common Stock","published_at":"2026-02-11T02:10:25.000Z","date":"2026-02-06","kind":"sale","planned":true,"acquired":false,"shares":29951,"price":2.4297,"value":72771.9447,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":156779,"source":{"system":"sec-edgar","filing":"0002018766-26-000006","document":"wk-form4_1770775823.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201876626000006/wk-form4_1770775823.xml","form_type":"4"}},{"id":912075,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-11T02:09:41.000Z","date":"2026-02-09","kind":"sale","planned":false,"acquired":false,"shares":889,"price":2.3929,"value":2127.2881,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":79133,"source":{"system":"sec-edgar","filing":"0001500189-26-000004","document":"wk-form4_1770775778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000150018926000004/wk-form4_1770775778.xml","form_type":"4"}},{"id":912074,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-11T02:09:41.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":7866,"price":2.4297,"value":19112.0202,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":80022,"source":{"system":"sec-edgar","filing":"0001500189-26-000004","document":"wk-form4_1770775778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000150018926000004/wk-form4_1770775778.xml","form_type":"4"}},{"id":919449,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and PFO"}}],"security":"Common Stock","published_at":"2026-02-05T01:27:50.000Z","date":"2026-02-03","kind":"sale","planned":true,"acquired":false,"shares":556,"price":2.515,"value":1398.34,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person."}],"balance_after":186730,"source":{"system":"sec-edgar","filing":"0002018766-26-000004","document":"wk-form4_1770254867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201876626000004/wk-form4_1770254867.xml","form_type":"4"}},{"id":919448,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and PFO"}}],"security":"Common Stock","published_at":"2026-02-05T01:27:50.000Z","date":"2026-02-02","kind":"sale","planned":true,"acquired":false,"shares":2540,"price":2.55,"value":6477.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":187286,"source":{"system":"sec-edgar","filing":"0002018766-26-000004","document":"wk-form4_1770254867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201876626000004/wk-form4_1770254867.xml","form_type":"4"}},{"id":942153,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and PFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:36:10.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":100000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Stock Option","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0002018766-26-000002","document":"wk-form4_1768008966.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000201876626000002/wk-form4_1768008966.xml","form_type":"4"}},{"id":942152,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:35:35.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":100000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001664928-26-000003","document":"wk-form4_1768008932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000166492826000003/wk-form4_1768008932.xml","form_type":"4"}},{"id":942151,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:34:52.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":365000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":365000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":365000},"source":{"system":"sec-edgar","filing":"0001838041-26-000002","document":"wk-form4_1768008888.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000183804126000002/wk-form4_1768008888.xml","form_type":"4"}},{"id":942147,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:33:08.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":775000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":775000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":775000},"source":{"system":"sec-edgar","filing":"0001500189-26-000002","document":"wk-form4_1768008785.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000150018926000002/wk-form4_1768008785.xml","form_type":"4"}},{"id":943455,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":21771,"kind":"organization","name":"WALTERS GROUP","position":1,"cik":"0001177523","reported_name":"WALTERS GROUP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21772,"kind":"person","name":"WALTERS WILLIAM THURMAN","position":2,"cik":"0001689655","reported_name":"WALTERS WILLIAM THURMAN","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":21773,"kind":"person","name":"WALTERS SUSAN BERKLEY","position":3,"cik":"0001689761","reported_name":"WALTERS SUSAN BERKLEY","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-08T21:57:05.000Z","date":"2025-12-31","kind":"purchase","planned":false,"acquired":true,"shares":6459973,"price":1.2,"value":7751967.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares of common stock reported herein (the \"Shares\") are held directly by The Walters Group (the \"TWG\"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The shares of common stock reported herein (the \"Shares\") are held directly by The Walters Group (the \"TWG\"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The shares of common stock reported herein (the \"Shares\") are held directly by The Walters Group (the \"TWG\"). William T. Walters may be deemed to share voting and dispositive power with respect to the Shares. Susan B. Walters is the general partner and majority member of TWG and may be deemed to share voting and dispositive power with respect to the Shares. Each Reporting Person disclaims Section 16 beneficial ownership of the Shares reported herein except to the extent of its pecuniary interest therein, if any, and the inclusion of these Shares in this report shall not be deemed an admission of beneficial ownership of any of the reported Shares for purposes of Section 16 or any other purpose."}],"balance_after":13509973,"source":{"system":"sec-edgar","filing":"0001213900-26-002567","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1177523/000121390026002567/ownership.xml","form_type":"4"}},{"id":969513,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":48315,"kind":"organization","name":"Matrix Capital Management Company, LP","position":1,"cik":"0001410830","reported_name":"Matrix Capital Management Company, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":48316,"kind":"person","name":"GOEL DAVID E.","position":2,"cik":"0001548144","reported_name":"GOEL DAVID E.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2025-12-15T22:24:17.000Z","date":"2025-12-15","kind":"sale","planned":false,"acquired":false,"shares":7500000,"price":1.33,"value":9975000.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by Matrix Capital Management Master Fund, LP (the \"Matrix Fund\"). Matrix Capital Management Company, LP (the \"Investment Manager\"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel (\"Mr. Goel\", and together with the Investment Manager, the \"Reporting Persons\"), serves as the Managing General Partner of the Investment Manager."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":6459973,"source":{"system":"sec-edgar","filing":"0000902664-25-005288","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000090266425005288/ownership.xml","form_type":"4"}},{"id":1029387,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":69666,"kind":"person","name":"Bucher James B","position":1,"cik":"0001664928","reported_name":"Bucher James B","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-01T22:40:25.000Z","date":"2025-10-01","kind":"grant","planned":false,"acquired":true,"shares":400000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over a four-year period as follows: 25% of the options will vest on October 1, 2026, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":400000,"derivative":{"exercise_price":1.54,"expiration_date":"2025-09-30","underlying":"Common Stock","underlying_shares":400000},"source":{"system":"sec-edgar","filing":"0001664928-25-000008","document":"wk-form4_1759358422.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000166492825000008/wk-form4_1759358422.xml","form_type":"4"}},{"id":1106358,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":35157,"kind":"person","name":"Walker Luke Nathaniel","position":1,"cik":"0001701440","reported_name":"Walker Luke Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:19:09.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":144284,"source":{"system":"sec-edgar","filing":"0001725160-25-000137","document":"wk-form4_1750277940.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000137/wk-form4_1750277940.xml","form_type":"4"}},{"id":1106357,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:17:03.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":207154,"source":{"system":"sec-edgar","filing":"0001725160-25-000135","document":"wk-form4_1750277814.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000135/wk-form4_1750277814.xml","form_type":"4"}},{"id":1106991,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:15:49.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":250421,"source":{"system":"sec-edgar","filing":"0001725160-25-000133","document":"wk-form4_1750277742.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516025000133/wk-form4_1750277742.xml","form_type":"4"}},{"id":1106356,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36822,"kind":"person","name":"Kariuki Enoch","position":1,"cik":"0001843119","reported_name":"Kariuki Enoch","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:14:02.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":137365,"source":{"system":"sec-edgar","filing":"0001725160-25-000131","document":"wk-form4_1750277634.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000131/wk-form4_1750277634.xml","form_type":"4"}},{"id":1106355,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-18T20:12:25.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":57603,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 17, 2026 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":338795,"source":{"system":"sec-edgar","filing":"0001725160-25-000129","document":"wk-form4_1750277537.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000129/wk-form4_1750277537.xml","form_type":"4"}},{"id":1163389,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-04-30T21:07:20.000Z","date":"2025-04-30","kind":"purchase","planned":false,"acquired":true,"shares":21000,"price":1.3987,"value":29372.7,"ownership":{"direct":true},"balance_after":281192,"source":{"system":"sec-edgar","filing":"0001725160-25-000094","document":"wk-form4_1746047232.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000094/wk-form4_1746047232.xml","form_type":"4"}},{"id":1271744,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-12T22:00:31.000Z","date":"2025-02-06","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":2.2828,"value":45656.0,"ownership":{"direct":true},"balance_after":36629,"source":{"system":"sec-edgar","filing":"0001725160-25-000047","document":"wk-form4_1739397624.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000047/wk-form4_1739397624.xml","form_type":"4"}},{"id":1281934,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and Interim PFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T23:33:02.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":35633,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":35633,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":35633},"source":{"system":"sec-edgar","filing":"0001725160-25-000043","document":"wk-form4_1738798376.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000043/wk-form4_1738798376.xml","form_type":"4"}},{"id":1281933,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and Interim PFO"}}],"security":"Common Stock","published_at":"2025-02-05T23:33:02.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":2615,"price":1.7115,"value":4475.5725,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":189826,"source":{"system":"sec-edgar","filing":"0001725160-25-000043","document":"wk-form4_1738798376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000043/wk-form4_1738798376.xml","form_type":"4"}},{"id":1281932,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PAO and Interim PFO"}}],"security":"Common Stock","published_at":"2025-02-05T23:33:02.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":158586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":192441,"source":{"system":"sec-edgar","filing":"0001725160-25-000043","document":"wk-form4_1738798376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000043/wk-form4_1738798376.xml","form_type":"4"}},{"id":1281931,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T23:32:31.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":124714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":124714,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":124714},"source":{"system":"sec-edgar","filing":"0001725160-25-000041","document":"wk-form4_1738798344.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000041/wk-form4_1738798344.xml","form_type":"4"}},{"id":1281930,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-05T23:32:31.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":14368,"price":1.7115,"value":24590.832,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":512856,"source":{"system":"sec-edgar","filing":"0001725160-25-000041","document":"wk-form4_1738798344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000041/wk-form4_1738798344.xml","form_type":"4"}},{"id":1281929,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-02-05T23:32:31.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":335907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":527224,"source":{"system":"sec-edgar","filing":"0001725160-25-000041","document":"wk-form4_1738798344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000041/wk-form4_1738798344.xml","form_type":"4"}},{"id":1281926,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T23:30:36.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":16629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":16629,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":16629},"source":{"system":"sec-edgar","filing":"0001725160-25-000037","document":"wk-form4_1738798229.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000037/wk-form4_1738798229.xml","form_type":"4"}},{"id":1281925,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2025-02-05T23:30:36.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":16629,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":16629,"source":{"system":"sec-edgar","filing":"0001725160-25-000037","document":"wk-form4_1738798229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000037/wk-form4_1738798229.xml","form_type":"4"}},{"id":1281928,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T23:29:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":59388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":59388,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":59388},"source":{"system":"sec-edgar","filing":"0001725160-25-000036","document":"wk-form4_1738798191.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000036/wk-form4_1738798191.xml","form_type":"4"}},{"id":1281927,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-05T23:29:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":59388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":87888,"source":{"system":"sec-edgar","filing":"0001725160-25-000036","document":"wk-form4_1738798191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000036/wk-form4_1738798191.xml","form_type":"4"}},{"id":1282129,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T18:31:59.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":124714,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":124714,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":124714},"source":{"system":"sec-edgar","filing":"0001725160-25-000040","document":"wk-form4_1738798313.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516025000040/wk-form4_1738798313.xml","form_type":"4"}},{"id":1282128,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-05T18:31:59.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":13230,"price":1.7115,"value":22643.145,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":1070784,"source":{"system":"sec-edgar","filing":"0001725160-25-000040","document":"wk-form4_1738798313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516025000040/wk-form4_1738798313.xml","form_type":"4"}},{"id":1282127,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-02-05T18:31:59.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":934041,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":1084014,"source":{"system":"sec-edgar","filing":"0001725160-25-000040","document":"wk-form4_1738798313.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516025000040/wk-form4_1738798313.xml","form_type":"4"}},{"id":1284941,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:45:00.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":60000,"price":1.7241,"value":103446.0,"ownership":{"direct":true},"balance_after":149551,"source":{"system":"sec-edgar","filing":"0001725160-25-000030","document":"wk-form4_1738705494.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000030/wk-form4_1738705494.xml","form_type":"4"}},{"id":1284940,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":35157,"kind":"person","name":"Walker Luke Nathaniel","position":1,"cik":"0001701440","reported_name":"Walker Luke Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-04T21:43:58.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":14200,"price":1.7582,"value":24966.44,"ownership":{"direct":true},"balance_after":86681,"source":{"system":"sec-edgar","filing":"0001725160-25-000029","document":"wk-form4_1738705431.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000029/wk-form4_1738705431.xml","form_type":"4"}},{"id":1284939,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-04T21:37:15.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":28500,"price":1.7314,"value":49344.9,"ownership":{"direct":true},"balance_after":28500,"source":{"system":"sec-edgar","filing":"0001725160-25-000028","document":"wk-form4_1738705022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000028/wk-form4_1738705022.xml","form_type":"4"}},{"id":1314907,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-03T22:17:05.000Z","date":"2025-01-02","kind":"sale","planned":false,"acquired":false,"shares":4411,"price":3.12,"value":13762.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":191317,"source":{"system":"sec-edgar","filing":"0001725160-25-000002","document":"wk-form4_1735942617.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000002/wk-form4_1735942617.xml","form_type":"4"}},{"id":1345122,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67047,"kind":"person","name":"Bruns Ingmar","position":1,"cik":"0001838041","reported_name":"Bruns Ingmar","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T00:02:41.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":712650,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over a four-year period as follows: 25% of the options will vest on November 13, 2025, with the remaining 75% vesting in substantially equal monthly installments thereafter until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":712650,"derivative":{"exercise_price":3.66,"expiration_date":"2034-12-02","underlying":"Common Stock","underlying_shares":712650},"source":{"system":"sec-edgar","filing":"0001725160-24-000190","document":"wk-form4_1733270555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000190/wk-form4_1733270555.xml","form_type":"4"}},{"id":1345121,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T00:02:15.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":3028800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over a four-year period following the vesting commencement date of November 13, 2024, in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":3028800,"derivative":{"exercise_price":3.66,"expiration_date":"2034-12-02","underlying":"Common Stock","underlying_shares":3028800},"source":{"system":"sec-edgar","filing":"0001725160-24-000189","document":"wk-form4_1733270528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000189/wk-form4_1733270528.xml","form_type":"4"}},{"id":1366633,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36821,"kind":"person","name":"Myers Scott Dunseth","position":1,"cik":"0001356256","reported_name":"Myers Scott Dunseth","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-11-13T22:46:58.000Z","date":"2024-11-13","kind":"grant","planned":false,"acquired":true,"shares":260192,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (\"RSUs\") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":260192,"source":{"system":"sec-edgar","filing":"0001725160-24-000186","document":"wk-form4_1731538012.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000186/wk-form4_1731538012.xml","form_type":"4"}},{"id":1390801,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":67046,"kind":"person","name":"Vultaggio Vincent","position":1,"cik":"0002018766","reported_name":"Vultaggio Vincent","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Principal Accounting Officer"}}],"security":"Common Stock","published_at":"2024-10-04T22:01:21.000Z","date":"2024-10-04","kind":"sale","planned":true,"acquired":false,"shares":1603,"price":3.18,"value":5097.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"A portion of the shares were sold automatically to satisfy withholding tax obligations upon the vesting of restricted stock units, and the remainder of the shares were sold pursuant to a Rule 10b5-1 instruction adopted by the Reporting Person on September 20, 2023."}],"balance_after":33855,"source":{"system":"sec-edgar","filing":"0001725160-24-000163","document":"wk-form4_1728079274.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000163/wk-form4_1728079274.xml","form_type":"4"}},{"id":1472111,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T21:11:02.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":41581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":89551,"source":{"system":"sec-edgar","filing":"0001725160-24-000145","document":"wk-form4_1719004255.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000145/wk-form4_1719004255.xml","form_type":"4"}},{"id":1472110,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36822,"kind":"person","name":"Kariuki Enoch","position":1,"cik":"0001843119","reported_name":"Kariuki Enoch","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T21:09:42.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":41581,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":79762,"source":{"system":"sec-edgar","filing":"0001725160-24-000143","document":"wk-form4_1719004175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000143/wk-form4_1719004175.xml","form_type":"4"}},{"id":1472603,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-21T21:07:33.000Z","date":"2024-06-21","kind":"grant","planned":false,"acquired":true,"shares":48429,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 21, 2025 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":192818,"source":{"system":"sec-edgar","filing":"0001725160-24-000141","document":"wk-form4_1719004045.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516024000141/wk-form4_1719004045.xml","form_type":"4"}},{"id":1496731,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President, Interim CFO"}}],"security":"Common Stock","published_at":"2024-05-31T22:27:15.000Z","date":"2024-05-31","kind":"sale","planned":false,"acquired":false,"shares":9597,"price":11.98,"value":114972.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":633680,"source":{"system":"sec-edgar","filing":"0001725160-24-000127","document":"wk-form4_1717194425.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000127/wk-form4_1717194425.xml","form_type":"4"}},{"id":1499183,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":35157,"kind":"person","name":"Walker Luke Nathaniel","position":1,"cik":"0001701440","reported_name":"Walker Luke Nathaniel","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-29T11:34:11.000Z","date":"2024-05-24","kind":"grant","planned":false,"acquired":true,"shares":72481,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (\"RSUs\") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":72481,"source":{"system":"sec-edgar","filing":"0001725160-24-000123","document":"wk-form4_1716982442.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000123/wk-form4_1716982442.xml","form_type":"4"}},{"id":1522175,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":39170,"kind":"person","name":"HAUSMAN DIANA","position":1,"cik":"0001563992","reported_name":"HAUSMAN DIANA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-05-09T23:46:59.000Z","date":"2024-05-09","kind":"sale","planned":false,"acquired":false,"shares":3356,"price":12.62,"value":42352.72,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":373876,"source":{"system":"sec-edgar","filing":"0001725160-24-000111","document":"wk-form4_1715298409.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000111/wk-form4_1715298409.xml","form_type":"4"}},{"id":1649467,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-13T01:22:44.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":2573,"price":11.44,"value":29435.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":451449,"source":{"system":"sec-edgar","filing":"0001725160-24-000043","document":"wk-form4_1707787354.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000043/wk-form4_1707787354.xml","form_type":"4"}},{"id":1649372,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-02-13T01:21:42.000Z","date":"2024-02-12","kind":"sale","planned":false,"acquired":false,"shares":1173,"price":11.44,"value":13419.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.29 to $11.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":643277,"source":{"system":"sec-edgar","filing":"0001725160-24-000041","document":"wk-form4_1707787292.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000041/wk-form4_1707787292.xml","form_type":"4"}},{"id":1658985,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":39170,"kind":"person","name":"HAUSMAN DIANA","position":1,"cik":"0001563992","reported_name":"HAUSMAN DIANA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:16:23.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":337500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. The options will vest over four years in equal monthly installments from the vesting commencement date of January 19, 2024 until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":337500,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":337500},"source":{"system":"sec-edgar","filing":"0001725160-24-000036","document":"wk-form4_1707178572.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000036/wk-form4_1707178572.xml","form_type":"4"}},{"id":1658984,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":39170,"kind":"person","name":"HAUSMAN DIANA","position":1,"cik":"0001563992","reported_name":"HAUSMAN DIANA","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:16:23.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":337500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person in connection with Reporting Person's previously disclosed appointment as Chief Medical Officer, effective January 19, 2024. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments over a four year period following the vesting commencement date of January 19, 2024, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":377232,"source":{"system":"sec-edgar","filing":"0001725160-24-000036","document":"wk-form4_1707178572.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000036/wk-form4_1707178572.xml","form_type":"4"}},{"id":1658983,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:15:34.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":141000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Scientific Officer, a role to which he was promoted on December 31, 2023."}],"balance_after":141000,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":141000},"source":{"system":"sec-edgar","filing":"0001725160-24-000034","document":"wk-form4_1707178516.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000034/wk-form4_1707178516.xml","form_type":"4"}},{"id":1658982,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:15:34.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":1585,"price":11.54,"value":18290.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":195728,"source":{"system":"sec-edgar","filing":"0001725160-24-000034","document":"wk-form4_1707178516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000034/wk-form4_1707178516.xml","form_type":"4"}},{"id":1658981,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:15:34.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":141000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":197313,"source":{"system":"sec-edgar","filing":"0001725160-24-000034","document":"wk-form4_1707178516.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000034/wk-form4_1707178516.xml","form_type":"4"}},{"id":1658980,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:13:51.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":192500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":192500,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":192500},"source":{"system":"sec-edgar","filing":"0001725160-24-000030","document":"wk-form4_1707178402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000030/wk-form4_1707178402.xml","form_type":"4"}},{"id":1658979,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-02-06T00:13:51.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":11552,"price":11.54,"value":133310.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":644450,"source":{"system":"sec-edgar","filing":"0001725160-24-000030","document":"wk-form4_1707178402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000030/wk-form4_1707178402.xml","form_type":"4"}},{"id":1658978,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2024-02-06T00:13:51.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":192500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":656002,"source":{"system":"sec-edgar","filing":"0001725160-24-000030","document":"wk-form4_1707178402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000030/wk-form4_1707178402.xml","form_type":"4"}},{"id":1659088,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-06T00:12:40.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":75000,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001725160-24-000028","document":"wk-form4_1707178346.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000028/wk-form4_1707178346.xml","form_type":"4"}},{"id":1659087,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:12:40.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":8669,"price":11.54,"value":100040.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":454022,"source":{"system":"sec-edgar","filing":"0001725160-24-000028","document":"wk-form4_1707178346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000028/wk-form4_1707178346.xml","form_type":"4"}},{"id":1659086,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-06T00:12:40.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":462691,"source":{"system":"sec-edgar","filing":"0001725160-24-000028","document":"wk-form4_1707178346.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516024000028/wk-form4_1707178346.xml","form_type":"4"}},{"id":1659198,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T19:14:48.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":90000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The options were granted to the Reporting Person in connection with Reporting Person's promotion to Chief Legal Officer, which became effective February 1, 2024. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":90000,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":90000},"source":{"system":"sec-edgar","filing":"0001725160-24-000032","document":"wk-form4_1707178473.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516024000032/wk-form4_1707178473.xml","form_type":"4"}},{"id":1659197,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T19:14:48.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer. The options are Reporting Person's annual equity grants, which reflect the market data for Reporting Person's role as Chief Legal Officer, a role to which she was promoted on February 1, 2024."}],"balance_after":112500,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001725160-24-000032","document":"wk-form4_1707178473.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516024000032/wk-form4_1707178473.xml","form_type":"4"}},{"id":1659196,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:14:48.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":3310,"price":11.54,"value":38197.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $11.35 to $11.64. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":149973,"source":{"system":"sec-edgar","filing":"0001725160-24-000032","document":"wk-form4_1707178473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516024000032/wk-form4_1707178473.xml","form_type":"4"}},{"id":1659195,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83561,"kind":"person","name":"Paul Andrea","position":1,"cik":"0001863130","reported_name":"Paul Andrea","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:14:48.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":153283,"source":{"system":"sec-edgar","filing":"0001725160-24-000032","document":"wk-form4_1707178473.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1863130/000172516024000032/wk-form4_1707178473.xml","form_type":"4"}},{"id":1659121,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":38783,"kind":"person","name":"Blackwell Kimberly","position":1,"cik":"0001816465","reported_name":"Blackwell Kimberly","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-05T19:11:29.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":250000,"derivative":{"exercise_price":11.69,"expiration_date":"2034-01-31","underlying":"Common Stock","underlying_shares":250000},"source":{"system":"sec-edgar","filing":"0001725160-24-000026","document":"wk-form4_1707178279.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1816465/000172516024000026/wk-form4_1707178279.xml","form_type":"4"}},{"id":1659120,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":38783,"kind":"person","name":"Blackwell Kimberly","position":1,"cik":"0001816465","reported_name":"Blackwell Kimberly","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:11:29.000Z","date":"2024-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":20655,"price":11.69,"value":241456.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Shares automatically withheld to satisfy tax obligations upon the vesting of restricted stock units previously granted to the Reporting Person."}],"balance_after":484145,"source":{"system":"sec-edgar","filing":"0001725160-24-000026","document":"wk-form4_1707178279.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1816465/000172516024000026/wk-form4_1707178279.xml","form_type":"4"}},{"id":1659119,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":38783,"kind":"person","name":"Blackwell Kimberly","position":1,"cik":"0001816465","reported_name":"Blackwell Kimberly","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2024-02-05T19:11:29.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":250000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":504800,"source":{"system":"sec-edgar","filing":"0001725160-24-000026","document":"wk-form4_1707178279.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816465/000172516024000026/wk-form4_1707178279.xml","form_type":"4"}},{"id":1692676,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-01-04T01:21:08.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options were granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. The options will vest over four years in equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":60000,"derivative":{"exercise_price":15.99,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001725160-24-000004","document":"wk-form4_1704331256.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000004/wk-form4_1704331256.xml","form_type":"4"}},{"id":1692675,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":83558,"kind":"person","name":"Lackner Mark","position":1,"cik":"0001777413","reported_name":"Lackner Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T01:21:08.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted to the Reporting Person in connection with Reporting Person's previously disclosed promotion to Chief Scientific Officer, which became effective December 31, 2023. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of December 31, 2023, subject to the Reporting Person's continuing service with the Issuer."}],"balance_after":56313,"source":{"system":"sec-edgar","filing":"0001725160-24-000004","document":"wk-form4_1704331256.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000004/wk-form4_1704331256.xml","form_type":"4"}},{"id":1702826,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":95975,"kind":"person","name":"Bunker Kevin D.","position":1,"cik":"0001807484","reported_name":"Bunker Kevin D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-12-21T17:47:53.000Z","date":"2023-12-20","kind":"gift","planned":false,"acquired":false,"shares":24158,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The Reporting Person transferred 24,158 shares to the Raising Hope Foundation, a charitable foundation of which the Reporting Person is a director. The Reporting Person has voting and investment power over all securities owned by the Raising Hope Foundation."}],"balance_after":834931,"source":{"system":"sec-edgar","filing":"0001725160-23-000203","document":"wk-form4_1703198862.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807484/000172516023000203/wk-form4_1703198862.xml","form_type":"4"}},{"id":1745110,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-11-13T22:24:19.000Z","date":"2023-11-10","kind":"purchase","planned":false,"acquired":true,"shares":17000,"price":9.879,"value":167943.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $9.70 to $9.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":144389,"source":{"system":"sec-edgar","filing":"0001725160-23-000201","document":"wk-form4_1699914237.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516023000201/wk-form4_1699914237.xml","form_type":"4"}},{"id":1744138,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":38783,"kind":"person","name":"Blackwell Kimberly","position":1,"cik":"0001816465","reported_name":"Blackwell Kimberly","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2023-11-13T17:24:08.000Z","date":"2023-11-13","kind":"purchase","planned":false,"acquired":true,"shares":5000,"price":10.2896,"value":51448.0,"ownership":{"direct":true},"balance_after":254800,"source":{"system":"sec-edgar","filing":"0001725160-23-000200","document":"wk-form4_1699914229.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1816465/000172516023000200/wk-form4_1699914229.xml","form_type":"4"}},{"id":1763702,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-06T23:18:52.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":888,"price":19.9102,"value":17680.2576,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023."}],"balance_after":387691,"source":{"system":"sec-edgar","filing":"0001725160-23-000179","document":"wk-form4_1696634321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000179/wk-form4_1696634321.xml","form_type":"4"}},{"id":1763701,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":29304,"kind":"person","name":"Epperly Melissa B,","position":1,"cik":"0001807359","reported_name":"Epperly Melissa B,","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-10-06T23:18:52.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":4594,"price":19.4265,"value":89245.341,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 1,125 shares acquired under the Zentalis Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan on March 31, 2023."}],"balance_after":388579,"source":{"system":"sec-edgar","filing":"0001725160-23-000179","document":"wk-form4_1696634321.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807359/000172516023000179/wk-form4_1696634321.xml","form_type":"4"}},{"id":1763806,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":77482,"kind":"person","name":"Brownstein Carrie","position":1,"cik":"0001894232","reported_name":"Brownstein Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-10-06T19:19:49.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":1722,"price":19.9102,"value":34285.3644,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":105685,"source":{"system":"sec-edgar","filing":"0001725160-23-000181","document":"wk-form4_1696634381.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1894232/000172516023000181/wk-form4_1696634381.xml","form_type":"4"}},{"id":1763805,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":77482,"kind":"person","name":"Brownstein Carrie","position":1,"cik":"0001894232","reported_name":"Brownstein Carrie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-10-06T19:19:49.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":8906,"price":19.4265,"value":173012.409,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":107407,"source":{"system":"sec-edgar","filing":"0001725160-23-000181","document":"wk-form4_1696634381.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1894232/000172516023000181/wk-form4_1696634381.xml","form_type":"4"}},{"id":1764027,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":95975,"kind":"person","name":"Bunker Kevin D.","position":1,"cik":"0001807484","reported_name":"Bunker Kevin D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-10-06T19:19:21.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":983,"price":19.9102,"value":19571.7266,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $19.91 to $19.93. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":859089,"source":{"system":"sec-edgar","filing":"0001725160-23-000180","document":"wk-form4_1696634351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1807484/000172516023000180/wk-form4_1696634351.xml","form_type":"4"}},{"id":1764026,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":95975,"kind":"person","name":"Bunker Kevin D.","position":1,"cik":"0001807484","reported_name":"Bunker Kevin D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-10-06T19:19:21.000Z","date":"2023-10-04","kind":"sale","planned":true,"acquired":false,"shares":5085,"price":19.4265,"value":98783.7525,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $18.91 to $19.90. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":860072,"source":{"system":"sec-edgar","filing":"0001725160-23-000180","document":"wk-form4_1696634351.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807484/000172516023000180/wk-form4_1696634351.xml","form_type":"4"}},{"id":1782108,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-13T20:11:17.000Z","date":"2023-09-11","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":25.0475,"value":125237.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires September 14, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $24.76 to $25.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":47970,"source":{"system":"sec-edgar","filing":"0001725160-23-000162","document":"wk-form4_1694635867.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000162/wk-form4_1694635867.xml","form_type":"4"}},{"id":1849629,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":48315,"kind":"organization","name":"Matrix Capital Management Company, LP","position":1,"cik":"0001410830","reported_name":"Matrix Capital Management Company, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":48316,"kind":"person","name":"GOEL DAVID E.","position":2,"cik":"0001548144","reported_name":"GOEL DAVID E.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock, par value $0.001 per share","published_at":"2023-06-20T20:30:54.000Z","date":"2023-06-20","kind":"purchase","planned":false,"acquired":true,"shares":4760000,"price":22.66,"value":107861600.0,"ownership":{"direct":false,"nature":"See footnotes"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The securities reported herein are held by Matrix Capital Management Master Fund, LP (the \"Matrix Fund\"). Matrix Capital Management Company, LP (the \"Investment Manager\"), a Delaware limited partnership, is the investment advisor to the Matrix Fund. Mr. David E. Goel (\"Mr. Goel\", and together with the Investment Manager, the \"Reporting Persons\"), serves as the Managing General Partner of the Investment Manager."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The filing of this statement shall not be deemed an admission that either of the Reporting Persons is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein."}],"balance_after":13959973,"source":{"system":"sec-edgar","filing":"0000902664-23-003642","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000090266423003642/ownership.xml","form_type":"4"}},{"id":1853467,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":37036,"kind":"person","name":"Johnson David Michael","position":1,"cik":"0001808098","reported_name":"Johnson David Michael","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:04:20.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":19059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":127389,"source":{"system":"sec-edgar","filing":"0001725160-23-000146","document":"wk-form4_1686949452.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1808098/000172516023000146/wk-form4_1686949452.xml","form_type":"4"}},{"id":1852372,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36822,"kind":"person","name":"Kariuki Enoch","position":1,"cik":"0001843119","reported_name":"Kariuki Enoch","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:02:38.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":16364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":38181,"source":{"system":"sec-edgar","filing":"0001725160-23-000143","document":"wk-form4_1686949344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000143/wk-form4_1686949344.xml","form_type":"4"}},{"id":1852369,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":36823,"kind":"person","name":"Skvarka Jan","position":1,"cik":"0001838042","reported_name":"Skvarka Jan","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-06-16T21:01:25.000Z","date":"2023-06-16","kind":"grant","planned":false,"acquired":true,"shares":16364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted pursuant to the Issuer's Non-Employee Director Compensation Program, each of which represents a contingent right to receive one share of common stock, and which will vest on the first to occur of (a) June 16, 2024 or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such vesting date."}],"balance_after":52970,"source":{"system":"sec-edgar","filing":"0001725160-23-000141","document":"wk-form4_1686949276.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000141/wk-form4_1686949276.xml","form_type":"4"}},{"id":1873376,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2023-06-01T01:10:35.000Z","date":"2023-05-31","kind":"sale","planned":true,"acquired":false,"shares":18526,"price":26.2079,"value":485527.5554,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires June 5, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $25.91 to $26.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":463502,"source":{"system":"sec-edgar","filing":"0001725160-23-000125","document":"wk-form4_1685581824.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000125/wk-form4_1685581824.xml","form_type":"4"}},{"id":1873375,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":51610,"kind":"person","name":"Gallagher Cam","position":1,"cik":"0001557832","reported_name":"Gallagher Cam","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2023-06-01T01:10:35.000Z","date":"2023-05-31","kind":"sale","planned":true,"acquired":false,"shares":9242,"price":26.3989,"value":243978.6338,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units."}],"balance_after":482028,"source":{"system":"sec-edgar","filing":"0001725160-23-000125","document":"wk-form4_1685581824.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000125/wk-form4_1685581824.xml","form_type":"4"}},{"id":1873940,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":95975,"kind":"person","name":"Bunker Kevin D.","position":1,"cik":"0001807484","reported_name":"Bunker Kevin D.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-05-31T21:09:52.000Z","date":"2023-05-26","kind":"sale","planned":true,"acquired":false,"shares":80000,"price":30.0156,"value":2401248.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sale reported in this Form 4 was effected pursuant to a plan that complies with Rule 10b5-1 and expires July 31, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $30.00 to $30.10. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Represents shares nominally held by Sundog Ranch, Inc. on behalf of the Bunker Family Protection Trust, the sole shareholder of Sundog Ranch, Inc. The Reporting Person and his wife are the primary beneficiaries of the Bunker Family Protection Trust and the Reporting Person and his wife are also directors of Sundog Ranch, Inc. The Reporting Person disclaims beneficial ownership of the securities held by Sundog Ranch, Inc. except to the extent of his pecuniary interest therein, if any."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001725160-23-000124","document":"wk-form4_1685581781.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807484/000172516023000124/wk-form4_1685581781.xml","form_type":"4"}},{"id":1898195,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":39170,"kind":"person","name":"HAUSMAN DIANA","position":1,"cik":"0001563992","reported_name":"HAUSMAN DIANA","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-10T11:13:15.000Z","date":"2023-05-08","kind":"grant","planned":false,"acquired":true,"shares":39732,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The restricted stock units (\"RSUs\") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date."}],"balance_after":39732,"source":{"system":"sec-edgar","filing":"0001725160-23-000116","document":"wf-form4_168371718549282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000116/wf-form4_168371718549282.xml","form_type":"4"}},{"id":1979707,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":116153,"kind":"person","name":"Roth Iris","position":1,"cik":"0001964808","reported_name":"Roth Iris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-03-02T21:30:11.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":297500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years: 25% of the options will vest on February 6, 2024, with the remaining 75% vesting in equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":297500,"derivative":{"exercise_price":18.87,"expiration_date":"2033-03-01","underlying":"Common Stock","underlying_shares":297500},"source":{"system":"sec-edgar","filing":"0001725160-23-000050","document":"wf-form4_167779259154330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000050/wf-form4_167779259154330.xml","form_type":"4"}},{"id":1979706,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":116153,"kind":"person","name":"Roth Iris","position":1,"cik":"0001964808","reported_name":"Roth Iris","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Operating Officer"}}],"security":"Common Stock","published_at":"2023-03-02T21:30:11.000Z","date":"2023-03-01","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments on the first, second, third and fourth anniversaries of the vesting commencement date of Feb. 6, 2023, subject to the Reporting Person's continuing service with the Issuer."}],"balance_after":52500,"source":{"system":"sec-edgar","filing":"0001725160-23-000050","document":"wf-form4_167779259154330.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516023000050/wf-form4_167779259154330.xml","form_type":"4"}}],"next_cursor":"2023-03-02T21:30:11.000000Z,1979706"}